Table 3

Bivariate (main immunogenic region and binding antibody before treatment) regression analysis of clinical factors

Clinical factors	R Value	AChR MIR Ab		AChR binding Ab
Clinical factors	R Value	Coefficient (95% CI)	p Value	Coefficient (95% CI)	p Value
Age (years)	−0.16	−0.13 (−0.30 to 0.04)	0.14	0.00 (−0.04 to 0.04)	0.91
Female sex	0.20	0.005 (0.000 to 0.009)	0.048^*	−0.000 (−0.001 to 0.001)	0.52
Age at onset (years)	−0.08	−0.01 (−0.22 to 0.20)	0.91	−0.02 (−0.07 to 0.03)	0.50
Time since onset (years)	−0.19	−0.12 (−0.25 to 0.02)	0.08	0.02 (−0.01 to 0.05)	0.23
EOMG	0.11	−0.001 (−0.006 to 0.004)	0.64	0.001 (−0.001 to 0.002)	0.30
LOMG	−0.21	−0.004 (−0.009 to −0.001)	0.11	−0.000 (−0.002 to 0.001)	0.57
Thymoma	0.25	0.005 (0.001 to 0.009)	0.016^*	−0.001 (−0.001 to 0.001)	0.59
Ocular MG	−0.62	−0.012 (−0.016 to −0.009)	<0.0001^*	−0.000 (−0.001 to 0.001)	0.64
Bulbar symptoms	0.45	0.010 (0.006 to 0.015)	<0.0001^*	0.000 (−0.001 to 0.001)	0.98
QMG score (n=30)	0.54	0.162 (0.046 to 0.278)	0.008^*	−0.002 (0.030 to 0.025)	0.86
MGFA classification (at worst condition)	0.44	0.024 (0.014 to 0.035)	<0.0001^*	−0.001 (−0.004 to 0.002)	0.40
Crisis	0.18	0.003 (0.000 to 0.006)	0.08	−0.000 (−0.001 to 0.000)	0.23
Post-intervention status
CSR	−0.13	−0.001 (−0.003 to 0.001)	0.29	−0.000 (−0.001 to 0.001)	0.99
PR or better	−0.09	−0.001 (−0.007 to 0.004)	0.66	−0.000 (−0.002 to 0.001)	0.70
MM-3 or better	−0.22	−0.004 (−0.009 to 0.001)	0.08	−0.000 (−0.001 to 0.001)	0.89

↵* Statistically significant (p<0.05).
n=102.
Ab, antibody; AChR, acetylcholine receptor; CSR, complete stable remission; EOMG, early onset myasthenia gravis; LOMG, late onset myasthenia gravis; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; MIR, main immunogenic region; MM, minimal manifestations; PR; pharmacological remission; QMG score, quantitative MG score.